Malgrat Pharma Chemicals S.L.U. operations in Catalonia, Spain. (Credit: AGC Inc.)
AGC Inc., a manufacturer of glass, chemicals, and high-tech materials, has entered into an agreement with Boehringer Ingelheim to acquire Malgrat Pharma Chemicals S.L.U. (MPC), a subsidiary of Boehringer Ingelheim that manufactures synthetic pharmaceutical active ingredients for the group.
By acquiring MPC, AGC will have its first FDA-registered site in Europe in the synthetic pharmaceutical CDMO business.
The deal remains subject to approval from the relevant antitrust authorities and the fulfillment of closing conditions under the share purchase agreement.
AGC Group sites engaged in life science. (Source: AGC Inc.)
MPC has experience manufacturing cGMP-compliant commercialized synthetic pharmaceuticals as well as compounds in clinical development on a range of scales.
Leveraging AGC’s fluorination technologies and experience in in-house drug discovery and the CDMO business built up in Japan, AGC, with the addition of MPC, plans to offer its CDMO services from a broader asset base, catering to European customer requirements and expanding its presence in the European market.
AGC’s management policy identifies life sciences as one of its strategic businesses. It plans to actively invest in the field to provide services to customers in both the synthetic drug and biopharmaceutical markets.
The company changed its name from Asahi Glass Co., Ltd. to AGC Inc. on July 1, 2018.
(Source: AGC Inc.)
